편도암에 대한 세기조절방사선치료의 예비적 결과 = The Preliminary Results of Intensity-Modulated Radiotherapy for Tonsillar Cancer

국문 초록 (Abstract)

목 적: 편도암 환자를 대상으로 시행한 세기조절방사선치료의 예비적 임상결과를 보고하고자 하였다. 대상 및 방법: 2002년 11월부터 2007년 2월까지 서울아산병원에서 세기조절방사선치료를 시행 받은 12명의 편도암 환자를 대상으로 후향적 분석을 시행하였다. 수술 후 방사선치료는 5명, 근치적방사선치료는 7명에서 시행되었고, 이중 6명의 환자가 cisplatin을 기본으로 하는 항암화학요법과 병용으로 치료를 받았다. 세기조절방사선치료는 9명의 환자에서 동시차등조사가속치료(simultaneous modulated accelerated radiation therapy)가 이용되었다. 근치적치료의 경우 일회선량 2.4 Gy 씩 총 72 Gy, 그리고 수술 후 치료의 경우 일회선량 2.2 Gy 씩 총 61.6 Gy의 방사선량이 조사되도록 하였다. 전체 환자의 추적 관찰 기간은 24∼80개월(중앙값 34개월)이었다.결 과: 전체 대상 환자 12명 모두 치료 중단 없이 계획된 치료를 수행 받았다. 방사선치료 종료 후 11명의 환자에서완전반응을 보였고 한 명의 환자에서 잔존림프절종양이 발견되어 구제 경부곽청술을 시행하였으나 3개월 후 국소림프절종양이 재발하였다. 완전 반응을 보인 11명의 환자는 마지막 추적 관찰 시점까지 국소림프절 재발 및 원격전이는 관찰되지 않았다. 치료 기간 중 급성 합병증은 Radiation Therapy Oncology Group 3도 이상의 구강 점막염,인두염과 구강건조증이 각각 3명, 3명, 6명에서 관찰되었다. 결 론: 세기조절방사선치료는 편도암의 치료에 있어서 초기 종양반응과 국소제어면에서 임상적으로 적용 가능한 치료법임을 확인 할 수 있었다. 향후 궁극적인 종양반응과 만성 합병증을 알기 위해서는 추가적인 연구대상과 추적관찰이 필요하겠다.

다국어 초록 (Multilingual Abstract)

Purpose: We wanted to present the preliminary results of intensity-modulated radiotherapy (IMRT) for the
treatment of tonsillar cancer. Materials and Methods: We retrospectively analyzed 12 patients who underwent IMRT for tonsillar cancer at Asan Medical Center between November 2002 and February 2007. Seven patients (58%) received definitive treatment, and five (42%) were treated in the postoperative setting. Among the definitively treated patients, 6 patients received cisplatin-based chemotherapy regimens. Simultaneous modulated accelerated radiation therapy (SMART) was used in nine patients. The prescribed dose was 72 Gy at 2.4 Gy/fraction for the definitively treated cases and 61.6 Gy at 2.2 Gy/fraction for the postoperative cases. The median follow-up period was 34 months. Results: All twelve patients completed treatment without interruption, and eleven showed a complete response. One patient had persistent loco-regional disease after treatment. The three-year estimates of loco-regional control, disease-free survival and overall survival were 91.7%, 91.7%, and 100%. The worst acute mucositis was Grade 1 in four patients, Grade 2 in five patients, Grade 3 in two patients and Grade 4 in one patient. Grade 3 xerostomia was observed in six patients. Conclusion: Intensity-modulated radiotherapy was shown to be a safe and effective treatment modality for tonsillar cancer. Further studies with a larger number of patients and a longer follow-up period are needed to evaluate the ultimate tumor control and late toxicity of IMRT for treating tonsillar cancer.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과
• 고안 및 결론

참고문헌 (Reference)

1 박진홍, "비인강암의 치료에서 동시차등조사가속치료를 적용한 제1상/2상 연구의 예비적 결과" 대한방사선종양학회 24 (24): 1-10, 2006

2 Chao KS, "prospective study of salivary function sparing in patients with head-and- neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results" 49 : 907-916, 2001

3 Cox JD, "Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)" 31 : 1341-1346, 1995

4 Wu Q, "The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments for head and neck cancers: a treatment design study" 46 : 195-205, 2000

5 Butler EB, "Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy" 45 : 21-32, 1999

6 Eisbruch A, "Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing" 59 : 28-42, 2004

7 Bjordal K, "Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy" 28 : 847-856, 1994

8 Sanguineti G, "Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma" 72 : 737-746, 2008

9 Chao KS, "Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer" 55 : 312-321, 2003

10 Schoenfeld GO, "Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer" 71 : 377-385, 2008

11 Kaplan EL, "Nonparametric estimation from incomplete observations" 53 : 457-481, 1958

12 Chao KS, "Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques" 61 : 275-280, 2001

13 Chao KS, "Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience" 90 : 92-103, 2000

14 Puri DR, "Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results" 28 : 415-423, 2005

15 de Arruda FF, "Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience" 64 : 363-373, 2006

16 Chao KS, "Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume" 59 : 43-50, 2004

17 Wolden SL, "Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial sloan-kettering experience" 64 : 57-62, 2006

18 Chao KS, "Dose prescription and target delineation for nodal volume" 2003

19 Devita VT, "DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 8th ed" 2005 839-844,

20 Central Cancer Registry Center, "Annual Report of the Central Cancer Registry in Korea, 2002" Ministry of Health and Welfare 2007

21 American Joint Committee on Cancer, "AJCC Cancer Staging Manual. 6th ed" Springer 2002

22 Fu KK, "A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003" 48 : 7-16, 2000